Inari Medical to Announce Fourth Quarter and Full-Year 2021 Financial Results

Rhea-AI Summary

Inari Medical (NASDAQ: NARI) will release its fourth quarter and full-year financial results on February 23, 2022. The company specializes in innovative medical devices for treating venous diseases.

Following the results announcement, Inari will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent highlights. Interested parties can access the live call via designated numbers or through the company's investor relations website.

Positive

• Release of important financial results on February 23, 2022.
• Innovative products aimed at treating venous diseases, with FDA and CE clearance.

Negative

• None.

IRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that it will release its fourth quarter and full-year financial results on Wednesday, February 23, 2022. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (833) 519-1265 for domestic callers or (914) 800-3838 for international callers, using conference ID: 3126888. The live webinar may be accessed by visiting the Events Section of the Inari investor relations website at ir.inarimedical.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on Inari’s website.

About Inari Medical, Inc.

Inari Medical, Inc. is a medical device company focused on developing innovative products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.

Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com

FAQ

When will Inari Medical announce its fourth quarter and full-year financial results?

Inari Medical will announce its financial results on February 23, 2022.

What time will the conference call for Inari Medical's financial results start?

The conference call will start at 1:30 p.m. PT / 4:30 p.m. ET.

How can I access Inari Medical's conference call?

You can access the call by dialing (833) 519-1265 for domestic callers or (914) 800-3838 for international callers, using conference ID 3126888.

What products does Inari Medical develop?

Inari Medical develops catheter-based mechanical thrombectomy devices for treating deep vein thrombosis and pulmonary embolism.